Could a diabetes pill help people with cirrhosis avoid deadly liver events?

NCT ID NCT07322237

Recruiting now Disease control Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated Apr 28, 2026 · Updated 13 times

Summary

This study tests whether adding empagliflozin (a diabetes drug) to standard carvedilol treatment can prevent serious liver complications or death in people with cirrhosis and a stiff heart condition. About 400 adults aged 18–65 with cirrhosis and left ventricular diastolic dysfunction will be randomly assigned to receive either empagliflozin or a placebo, plus carvedilol, for up to several years. The main goal is to see if the combination reduces episodes like internal bleeding, fluid buildup, or death.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

PGIMER Chandigarh
RECRUITING

Chandigarh, 160012, India

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CARDIOMETABOLIC RISK FACTORS CARDIOMETABOLIC RISK FACTORS CIRRHOSIS CIRRHOTIC CARDIOMYOPATHY EMPAGLIFLOZIN